Corporate Details
About Sosei Heptares
Our Leadership
Global Policies

Sosei Group Corporation

Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world-class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions. 

Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region. 

Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases. 

In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda. 

 

Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK. In July 2023, Sosei Heptares acquired all shares of Idorsia Pharmaceuticals Japan Ltd and Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd and Idorsia Pharmaceutical Ltd. 

“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. 

Established

June 22, 1990

Capital

46,807 million yen (as of 31 December 2023)

Scope of Business

Planning strategy for the entire Group and managing subsidiary companies

Representative Executive Officer, Chairman, President and Chief Executive Officer

Christopher Cargill

Securities Code

4565-JP

Accounting Period

12 months ended 31 December

Number of Employees

350 (consolidated figure, as of end of December 2023)

Corporate Headquarters

PMO Hanzomon 11F
2-1 Kojimachi, Chiyoda-ku
Tokyo 102-0083 Japan
Tel: +81-(0)3-5210-3290 (general enquiries)

Company Registration Number and Date

0100-01-021288 registered on 22 June 1990

Sosei Group Corporation London Branch

Scope of Business

Corporate representation in the UK

Address

North West House,
119 Marylebone Road,
London, NW1 5PU
United Kingdom
Tel: +44(0)1223 949 100

Company Registration Number and Date

FC024112 registered on 01 April 2002

UK Branch Registration Number and Date

BR006736 registered on 01 April 2002

VAT Number

GB 809812124

Group Companies

Sosei Co. Ltd.

Capital

JPY 90,000,000

Scope of Business

Drug development, manufacture and sales, and business development in Japan

Representative Director

Chris Cargill

Holding Company Stake

100%

Address

PMO Hanzomon 11F
2-1 Kojimachi, Chiyoda-ku
Tokyo 102-0083 Japan
Tel: +81-(0)3-5210-3290 (general enquiries)

Company Registration Number and Date

0100-01-103556 registered on 02 October 2006

Heptares Therapeutics Ltd.

Capital

GBP 416,000

Scope of Business

Drug discovery based on targeting of G protein-coupled receptors

Representative Director

Matt Barnes

Holding Company Stake

100%

Address

Steinmetz Building, Granta Park
Great Abington,
Cambridge CB21 6DG
United Kingdom
Tel: +44 (0)1223 949 100

Company Registration Number and Date

06267989 registered on 04 June 2007

VAT Number

GB 912562244

EORI Number

GB 912562244000

Data Protection Registration Number and Date

Z1055500 registered on 21 September 2007

Heptares Therapeutics Ireland Limited

Capital

EUR 100

Scope of Business

Corporate representation in the EU

Representative Director

Chris Cargill

Holding Company Stake

100% by Heptares Therapeutics Ltd in UK

Address

c/o Byrne Wallace LLP
88 Harcourt Street,
Dublin 2,
D02 DK18
Ireland

Company Registration Number and Date

656998 registered on 16 September 2019

Idorsia Pharmaceuticals Japan

CapitalCapital

 

JPY 95,000,000

 

Scope of Business

Drug manufacture and sales

 

Representative Director and President

Satoshi Tanaka

Holding Company Stake

100%

Address

Midtown East,
9-7-2 Akasaka Minato-ku
Tokyo 107-0052
Japan

Company Registration Number and Date

0100-01-190615 registered on 26 March 2018

Idorsia Pharmaceuticals Korea

Capital

 

KWR 100 mio.

Scope of Business

Drug manufacture and sales

Representative Director and Chairman

Satoshi Tanaka

Holding Company Stake

100%

Address

F17, 410 Teheran-Ro
GangNam-Gu
Seoul 06192
South Korea

Company Registration Number and Date

210-86-02517 registered on 7 July 2022